Y-mAbs Therapeutics A/S: Financial statements 2019
CVR: 37053678
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 52,032,447 and a net result of DKK -2,579,400 compared with DKK -4,193,681 the year before. That is an increase of 81.9% compared with the year before. Equity in the 2019 report amounted to DKK 4,035,074. The solvency ratio was 11.3%. The company had 36 employees in the financial year.
- Gross Profit
- DKK 52,032,447
- Profit/Loss
- DKK -2,579,400
- Equity
- DKK 4,035,074
- Total Assets
- DKK 35,736,437
- Employees
- 36
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 52M | -2.6M | 4M | 36 |
| 2018 | - | 28.6M | -4.2M | 1.6M | 19 |
| 2017 | - | 13.2M | -2.2M | 808K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of December 20, 2019, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK 28,598,680, and the net result was DKK -4,193,681.
About Y-mAbs Therapeutics A/S
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.
